Vascularised thick tissue: why you cannot buy it, and what you can buy instead

The short answer: you cannot buy vascularised thick human tissue, from anyone, as a catalogue item. This is the hard edge of the engineered tissue map, and unlike most gaps in this market it is not a commercial accident waiting for a supplier to notice. It is a physical constraint that the field has been working against for decades.

The constraint, stated in the literature: for a tissue to grow beyond 100–200 µm — the diffusion limit of oxygen — new blood-vessel formation is required. The same review notes that after implantation, diffusion supplies cells only within 100–200 µm of the nearest capillary.

Two hundred micrometres is about two sheets of paper. Everything the commercial tissue market sells is either thinner than that, small enough that its surface-to-volume ratio saves it, or perfused by an external pump through channels a manufacturer built.

What follows from this is the whole structure of the market. Skin, airway, gut and cornea models are thin sheets. Liver microtissues and organoids are small spheres. Organ-chips are thin tissue plus plumbing. There is no product category above the diffusion limit because there is no biology above the diffusion limit without a vasculature, and nobody has made a manufacturable one.

Why the limit binds so hard

Every cell in a metabolically active tissue needs oxygen delivered and carbon dioxide and waste removed. In the body, capillaries are spaced so that no cell sits much further than that distance from a supply. In a dish, the only transport mechanism is diffusion from the surface.

The failure mode is characteristic and instantly recognisable: a viable, proliferating outer rim and a dead core. Push a spheroid past a few hundred micrometres and the middle dies. That is the constraint expressing itself, and it is why organoid protocols have size ceilings rather than size targets.

Three consequences that matter commercially:

Thin is not a compromise, it is the design. A reconstructed epidermis at 8–12 cell layers or an airway model at 3–4 layers is not a simplified version of something thicker that suppliers are working toward. It is the thickness at which living tissue can be manufactured, shipped and kept alive without plumbing.

Small is the same answer in a different shape. A microtissue or spheroid solves the problem with geometry — high surface area relative to volume — rather than with thickness.

Perfusion is the third answer, and it is engineering rather than biology. Organ-chips push medium through channels next to or through the tissue. The vasculature is not grown; it is manufactured, and it is fixed at the moment the chip is moulded.

Anything that needs to be simultaneously thick, dense, metabolically active and self-supporting requires a real vascular network, and that is the thing nobody sells.

What actually ships in the vascular category

The category is not empty. It is just that everything in it is a model of vasculature, not a vasculature for thick tissue. A perfusable model on a chip answers questions about endothelium; it does not keep a millimetre-thick construct alive.

These are good products answering real questions. The angiogenesis model in particular reproduces genuine vascular biology — sprouting with tip-stalk hierarchy and anastomosis is the actual mechanism, not a proxy. But an angiogenesis assay in a plate is a model of the process. It is not a service that will vascularise a construct you send in.

What the literature has demonstrated

The research position is considerably more advanced than the commercial one, and it is worth knowing precisely what has been shown — both because it is genuinely impressive and because it is routinely overstated in pitch decks.

Printed vascular architecture in hydrogels. Grigoryan and colleagues showed in Science in 2019 that natural and synthetic food dyes can act as photoabsorbers enabling stereolithographic production of hydrogels containing intricate and functional vascular architectures, including entangled networks and functional intravascular topologies. This was a genuine step change in what geometry could be fabricated, and the photoabsorber insight is why it worked.

High cell density with embedded channels. Skylar-Scott and colleagues reported in Science Advances in 2019 a biomanufacturing method assembling hundreds of thousands of stem cell-derived organ building blocks into living matrices at high cellular density, into which perfusable vascular channels are introduced via embedded 3D printing. This attacked the density problem specifically — most printed tissue is far less cellular than real tissue — and it produced perfusable constructs.

The field’s own assessment. A 2025 Nature Biomedical Engineering review of vascular patterning strategies states directly that the survival of engineered tissues is constrained by the challenge of establishing a functional vasculature, and frames current work as inducing vascularisation in implants or stimulating vascular growth in recipients. That is a 2025 review describing an open problem, not a solved one.

Read those three together and the honest summary is: fabricating vascular geometry is demonstrated. Achieving high cell density with perfusable channels is demonstrated. Producing a thick, self-supporting, functionally vascularised human tissue as a manufacturable, shippable product is not — and the field says so in its own review literature.

What separates a demonstration from a product, in this specific case: the network must remain patent under flow for the life of the construct; the endothelium must be non-thrombogenic and stable; the tissue must survive shipping and handling with its perfusion interrupted; and it must be reproducible lot to lot rather than achieved once by a skilled group. Each of those is a research programme.

How to tell a real capability from a claim

Because this is an area with more announcements than products, a short interrogation protocol is useful. If a supplier offers vascularised thick tissue, ask:

1. What is the construct thickness, in micrometres, and what is the cell density? Both numbers, together. Thick and sparse is not the achievement; thick and dense is.
2. Is the vasculature grown or manufactured? A moulded channel is plumbing. A self-assembled, anastomosed, endothelialised network is vasculature. Both are legitimate — they are not the same claim.
3. Is it perfused, and by what? An external pump for the duration of the experiment is a capability. Blood or a blood substitute is not on offer anywhere.
4. What is the viability profile through the depth, measured with spatial resolution? A plate-reader average conceals a necrotic core completely. Ask for imaging through the thickness.
5. How long does it stay patent, and what is the failure mode when it does not?
6. How does it ship? Perfusion interrupted in transit is the question the whole cold chain turns on, and it is why this category has no cold chain.
7. What is the lot-to-lot reproducibility, across how many lots, made by how many operators?
8. Is there a published, peer-reviewed result for this specific construct, or a demonstration of a related one?

A supplier with a real capability will answer these comfortably. The questions are not hostile — they are the specification.

What to do instead, by objective

The useful move is almost always to attack the requirement rather than the constraint.

If you need more tissue, not thicker tissue. Scale in the plane, not in depth. More inserts, more wells, more spheroids. Almost every assay endpoint scales this way and it stays inside the manufacturable envelope.

If you need thickness for architecture. Ask whether the architecture can be represented in a thin construct. Full-thickness skin models exist commercially — epidermis plus dermis — precisely because that architecture can be built within the diffusion envelope. Airway models with fibroblast stromal compartments do the same thing.

If you need thickness for metabolic capacity. More small units beat one big unit. This is exactly why liver is sold as microtissues and spheroids rather than as a slab: total metabolic capacity is a count problem, and the count is cheap.

If you need flow. Buy an organ-chip and accept manufactured channels. The vasculature is not grown, but the transport problem is solved and the platform is real. The platform comparison covers the lock-in questions, which matter more than the biology when choosing.

If you need contractile bulk — the biohybrid robotics case — this constraint is why muscle constructs are thin strips and rings anchored between posts rather than blocks. The muscle actuator sourcing guide covers what is actually purchasable, and the geometry there is a consequence of the same physics.

If you genuinely need vascularised thick tissue. Then you have a research collaboration, not a purchase. It should be scoped, staged and funded as one, with a named academic group, defined milestones and an explicit possibility of failure. Anyone quoting it as a delivery is either redefining the term or is not describing what you asked for.

How to write the specification honestly

If you are putting this out to quote, the specification should make the constraint explicit so that responses are comparable and so that a vendor cannot answer a thinner question:

• Required construct dimensions, all three, in micrometres or millimetres.
• Required cell density, in cells per millilitre or per cubic millimetre.
• Metabolic requirement — the function that has to be sustained, and at what rate.
• Required viability through the depth, with the measurement method named.
• Perfusion: required or not; if required, by what medium, at what rate, driven by what.
• Duration: hours, days or weeks of maintained function.
• Whether the vasculature must be grown or may be manufactured. State this explicitly; it is the question that separates responses.
• Whether the construct must survive shipping, and in what state.
• Reproducibility requirement: how many constructs, to what tolerance.
• What happens if it is not achievable — the fallback design, stated up front.

That last item is the one that saves programmes. If the honest answer is that nobody can build it, the fallback should already be specified rather than improvised after six months.

The honest verdict

Available now: thin barrier tissue, small spheroids and microtissues, perfused organ-chips with manufactured channels, and in vitro vascular models of endothelium and angiogenesis. All real, all shipping, several with published specifications.

Demonstrated in the literature, not purchasable: printed vascular architectures in hydrogels, high-density organ building blocks with embedded perfusable channels, and a range of vascular patterning strategies under active review as of 2025.

Not available from anyone as a product: thick, dense, self-supporting, functionally vascularised human tissue.

That last line is not a gap we expect a supplier to fill next year, and we would rather say so than imply a quote is achievable. If your project depends on it, the right response is to redesign around the constraint or to fund the research — not to keep sending RFQs into a market that cannot answer them.

Where to go next

• Engineered tissue map — the availability clusters, and where the research-only categories sit.
• Organoids versus engineered tissue — the same diffusion limit seen from the model-class decision.
• Organ-on-chip platforms compared — the practical route to perfusion, and the lock-in questions.
• Muscle actuator sourcing — where thickness limits bite hardest outside toxicology.
• Custom organ-on-chip development — what a bespoke perfused build actually involves.

How we can help

The most useful thing we do in this category is tell people early that what they are asking for cannot be bought. That saves months of RFQs that return either silence or quotes for something adjacent and thinner.

If your specification is above the diffusion limit, we will say so plainly, then work with you on whether the requirement is really thickness — or capacity, architecture or flow, each of which has a purchasable answer today. If it genuinely is thickness with density and grown vasculature, we will point you toward the groups publishing in the area rather than toward a supplier who will take the order and disappoint you.

Tell us the dimensions, the density and the function that has to be sustained, and we will tell you honestly which side of the wall it falls on.